超越β阻塞:ACE抑制剂在高基利普级AMI患者中降低非心脏病死亡率
Simei Sun1,2, Xiongyi Han2,3, Liyan Bai2,4
1Department of Pharmacy, Zhoushan Hospital, Wenzhou Medical University, Zhoushan, China.
Journal of cardiovascular pharmacology and therapeutics
|July 21, 2024
概括
对于高基利普级急性心肌梗塞 (AMI),采用β-阻断剂 (BB) 加上血管酶转化酶抑制剂 (ACEI) 的治疗显示出比BB加上血管酶受体阻断剂 (ARB) 更好的结果. 在这些高风险AMI患者中,ACEI显示出对死亡率的优越预防作用.
科学领域:
- 心脏病学 心脏病学
- 临床医学 临床医学
- 药理学 药理学是指药理学的学科.
背景情况:
- 高基利普级 (III/IV) 急性心肌梗塞 (AMI) 表示严重的心脏功能障碍,预后不佳.
- 对这些高风险患者进行最佳的医学治疗对于改善临床结果至关重要.
- 对比抗胰岛素转化酶抑制剂 (ACEI) 和抗胰岛素受体阻断剂 (ARB) 与β阻断剂 (BB) 结合的比较对于指导治疗决策很重要.
研究的目的:
- 评估和比较高基利普级AMI患者的3年临床结果,这些患者接受BB + ACEI或BB + ARB治疗.
- 为了确定一个疗法是否能提供对主要心脏不良事件和死亡率的优越保护.
主要方法:
- 分析了来自韩国急性心肌梗塞登记处 (KAMIR-NIH) 871名高基利普级AMI患者的队列.
- 患者被分为两个组:BB + ACEI (n=489) 和BB + ARB (n=381).
- 倾向性得分匹配用于为每个组选择343名患者,确保在3年随访期间具有可比的基线特征.
主要成果:
- 虽然两组之间没有观察到心脏病死亡,复发性心脏病发作或重复PCI发生率的显著差异,但BB + ACEI组的风险明显较低.
- BB + ACEI 组有较低的重大心脏不良事件风险 (HR=0.574,p<.001),所有原因死亡率 (HR=0.561,p=.001) 和非心脏病死亡 (HR=0.365,p<.001).
结论:
- 在高基利普级AMI的患者中,β-阻断剂加上血管激素转化酶抑制剂 (BB + ACEI) 似乎比BB +血管激素受体阻断剂 (BB + ARB) 更有益.
- 在3年的时间里,BB + ACEI疗法在高风险AMI人群中显示出对死亡率的优越预防作用.
相关概念视频
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
418
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
418
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
594
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
594
Antihypertensive Drugs: Direct Renin Inhibitors
538
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
538
Antianginal Drugs: Nitrates and β-Blockers
571
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
571
Heart Failure Drugs: β-Blockers
336
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
336
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
486
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
486


